Drug Shortage Report for CEFTAZIDIME FOR INJECTION, USP
Report ID | 158756 |
Drug Identification Number | 00886971 |
Brand name | CEFTAZIDIME FOR INJECTION, USP |
Common or Proper name | Ceftazidime for Injection, USP |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | CEFTAZIDIME |
Strength(s) | 1G |
Dosage form(s) | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
Packaging size | 20mL |
ATC code | J01DD |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-04-30 |
Actual start date | 2022-04-30 |
Estimated end date | 2022-06-01 |
Actual end date | 2022-05-19 |
Shortage status | Resolved |
Updated date | 2022-05-24 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2022-04-13 | English | Compare |
v2 | 2022-04-13 | French | Compare |
v3 | 2022-04-26 | English | Compare |
v4 | 2022-04-26 | French | Compare |
v5 | 2022-05-01 | English | Compare |
v6 | 2022-05-24 | English | Compare |
v7 | 2022-05-24 | French | Compare |
Showing 1 to 7 of 7